Policy Interpretation - The policy marks a fundamental shift in the role of cell therapy, transitioning from an exploratory technology in laboratories to a core element in enhancing high-end medical supply capabilities and attracting international health consumption, aligning with Shanghai's strategy to become an international medical destination [6] - The policy aims to facilitate clinical use and encourage medical institutions to develop specialized international medical projects, providing a clear pathway for advanced therapies like cell therapy to enter standardized, high-quality medical service scenarios for high-demand cross-border patients [7] - The policy emphasizes the creation of a supportive ecosystem through innovative payment methods, diversified market participants, and strengthened industry chains, forming a sustainable health consumption service ecosystem [8] Practical Foundation - Shanghai's robust foundation in cell therapy is supported by regulatory and institutional innovations, including the introduction of specific provisions for cell and gene therapy in the local drug and medical device management regulations, establishing quality management requirements and encouraging collaboration between industry, academia, and insurance product development [9] - Shanghai has become a core area for the approval and clinical research of cell therapy products, with half of the nationally approved CAR-T cell therapy products originating from Shanghai, benefiting numerous patients with blood cancers. Notably, a universal CAR-NK cell therapy for systemic lupus erythematosus achieved a significant 67% response rate in difficult-to-treat patients, marking a leap to international standards in autoimmune disease cell therapy [12] - The successful completion of a cross-border CAR-T product preparation for an overseas patient within four hours demonstrates the regulatory collaboration and logistical efficiency of Shanghai's international cell therapy services, providing a practical model for health consumption globalization [16] - The Pudong New Area has attracted over 120 companies related to cell and gene industries, with more than 80 product-oriented companies, accounting for nearly one-third of the national clinical research pipelines, creating the densest innovation cluster in the country across various technical routes [18] Conclusion - The new policy positions cell therapy at the core of "international health consumption," representing a forward-looking strategic deployment that aims to build a comprehensive ecosystem encompassing technological innovation, clinical application, payment assurance, and international connectivity, enhancing Shanghai's health service capabilities and global competitiveness [19]